InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, is reporting on its second quarter of fiscal year 2023, the period that ended Dec. 31, 2022. Highlights of the report include the company closing the calendar year with nearly $11.5 million in cash and the completion of enrollment in the company’s phase 2 clinical trial in epidermolysis bullosa (“EB”). The report also noted that the company has seen advancement in its research using rare cannabinoids in the treatment of glaucoma and neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s. “This period was another strong operational quarter for the company as we advanced our pharmaceutical programs, including the launch of INM-900 series compounds for the evaluation of neurodegenerative diseases,” said InMed Pharmaceuticals president and CEO Eric A. Adams in the press release. “We are currently approaching the end of enrollment in our phase 2 clinical trial in epidermolysis bullosa. As we move into calendar 2023, we have a strong pipeline of programs at various stages of development. Fiscal Q2 saw significant cost savings across the different business segments resulting in a reduced cash burn. In addition, our strong cash position of over $11 million enables us to pursue several material milestones throughout calendar 2023.”
To view the full press release, visit https://ibn.fm/hnUSR
About InMed Pharmaceuticals Inc.
InMed Pharmaceuticals is a global leader in the research, development and manufacturing of rare cannabinoids, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. The company also has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, please visit www.InMedPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM
About TinyGems
TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.
To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.TinyGems.com
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer
TinyGems
Los Angeles, California
www.TinyGems.com
310.299.1717 Office
Editor@TinyGems.com
TinyGems is part of the InvestorBrandNetwork.
